1. Wilms (WTO 1) Unido a HLA-A2； Acido nucleo； vector de expression； phone para expression de anticopo； methodopara detection de WT1； composicion medianteutica； methodologa para murder cellnica WT1+； Kit para detection WT1； u； Comments more than a month ago
MEMORIAL SLOAN-KETTERING CANCER CENTER;EUREKA THERAPEUTICS, INC.,
发明人:
SCHEINBERG DAVID A.,DAO TAO,LIU CHENG,YAN SU
申请号：
CL2013002828
公开号：
CL2013002828A1
申请日:
2013.10.01
申请国别(地区):
CL
年份:
2014
代理人:
摘要：
The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.ANTICUERPO O FRAGMENTO DE UNION ESPECIFICO PARA LA PROTEINA DEL ONCOGEN DE WILMS (WT1) UNIDO A HLA-A2； ACIDO NUCLEICO； VECTOR DE EXPRESION； CELULA PARA LA EXPRESION DEL ANTICUERPO； METODO PARA LA DETECCION DE WT1； COMPOSICION FARMACEUTICA； METODO PARA MATAR CELULA WT1+； KIT PARA LA DETECCION WT1； USO PARA FABRICAR UN MEDICAMENTO
